Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management

Retrospective, Real-life Observational, Matched Cohort Evaluation of the Effectiveness of BDP/FOR (Fostair® 100/6) and FP/SAL (Seretide® 125) in Patients Switching From Seretide to Fostair in UK Primary Care Asthma Management

The purpose of this study is to evaluate whether beclomethasone dipropionate / formoterol (BDP/FOR; Fostair® 100/6) is at least equivalent in terms of exacerbation prevention to fluticasone dipropionate / salmeterol (FP/SAL; Seretide® 125) in matched asthma patients switching to BDP/FOR following treatment with FP/SAL in normal clinical practice compared with patients not switched.

Inclusion Criteria:

• Aged:

  • 18-60 years:
  • 61-80 years who are never-smokers

• Evidence of asthma:

  • a diagnostic code for asthma, or
  • ≥2 prescriptions for asthma at different points in time during the prior year

• Baseline FP/SAL therapy:

  • ≥2 prescription for ICS/LABA therapy as FP/SAL (Seretide® 125).

Exclusion Criteria:

• Any chronic respiratory disease other than asthma
• Are receiving maintenance oral steroid therapy during baseline period.